Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class
AMG 133 For Obesity Is One To Watch In CV Portfolio
Nov 08 2022
•
By
Mandy Jackson
About 20% of people have elevated Lp(a) levels that increase their cardiovascular disease risk • Source: Shutterstock
More from Clinical Trials
More from R&D